AstraZeneca COVID-19 vaccine shows 76% efficacy against symptomatic infection in updated data

AstraZeneca on Thursday published an updated analysis confirming that a Phase 3 trial involving its COVID-19 vaccine was safe and effective, and showed to be 76% effective against symptomatic COVID-19.